Document:

EXHIBIT 10.12

                              EMPLOYMENT AGREEMENT

THIS AGREEMENT made this 30 day of October, 2005.

BETWEEN:

            Oriens Life Sciences (Israel), Ltd., a body corporate duly
            registered in Israel with an address of 23 Aminadav St., Tel Aviv,
            Israel

            (the "Company")

AND:

            Tamar Tzaban-Nahomov, an individual currently residing at 6 Dov Hoz
            St., Kiryat Ono, Israel

            (the "Executive")

WHEREAS:

A. The Company has agreed to engage the Executive to serve in the role of the
Chief Financial Officer of the Company;

B. The Executive and the Company wish to formally record the terms and
conditions upon which the Executive will be employed by the Company and that
each of the Company and the Executive have agreed to the terms and conditions
set forth in this Agreement, as evidenced by their execution hereof.

NOW THEREFORE THIS AGREEMENT WITNESSES that in consideration of the premises and
the mutual covenants and agreements herein contained, the parties hereto
covenant and agree as follows:

                                   ARTICLE 1
                              CONTRACT FOR SERVICES

1.1   Engagement of Executive. Subject to earlier termination of the Agreement
      as hereinafter provided, the Company hereby agrees to employ the Executive
      in accordance with the terms and provisions hereof. The Executive shall
      serve as the CFO of the Company and shall perform her duties hereunder at
      the Company's facilities in Israel; however, the Executive acknowledges
      and agrees that the performance of her duties hereunder may require
      significant domestic and international travel.

1.2   Further Engagement of Executive. In addition, the Executive is employed as
      the CFO of the Company's parent company, SafeTek International Inc. (the
      "Parent Company"), without being entitled to any compensation other than
      the salary and additional compensation to which she is entitled pursuant
      to this Agreement.

<PAGE>

1.3   Term. Unless terminated earlier in accordance with the provisions hereof,
      the term of employment under this Agreement shall commence on September 1,
      2005 and shall continue until terminated by either party as provided
      herein (the "Term").

1.4   Exclusive Service. The Executive agrees to faithfully, honestly and
      diligently serve the Company and to devote the Executive's time, attention
      and best efforts to further the business and interests of the Company
      during the period of this Agreement, to the exclusion of all other
      engagements, except for those other engagements as shall be specifically
      authorized and approved by the CEO of the Company. The Executive agrees
      and undertakes to inform the CEO of the Company, immediately after
      becoming aware of any matter that may in any way raise a conflict of
      interest between the Executive and the Company. Nothing in this Section
      shall degrade from the Executive's obligation to devote her time to the
      business and interests of the Company, and to continue observing all of
      her undertakings under this Agreement in their entirety, including,
      without limitation, her obligations of confidentiality and non-disclosure.

1.5   Duties. The Executive's services hereunder shall be provided on the basis
      of the following terms and conditions:

      (a)   reporting directly to the Chief Executive Officer of the Company,
            the Executive shall serve as the CFO of the Company;

      (b)   the Executive shall be responsible for all finance affairs of the
            Company, all subject to any applicable law and to instructions
            provided by the CEO and the Board of Directors of the Company from
            time to time;

      (c)   the Executive shall faithfully, honestly and diligently serve the
            Company and cooperate with the Company and utilize maximum
            professional skill and care to ensure that all services rendered
            hereunder are to the satisfaction of the Company, acting reasonably,
            and the Executive shall provide any other services not specifically
            mentioned herein, but which by reason of the Executive's capability
            the Executive knows or ought to know to be necessary to ensure that
            the best interests of the Company are maintained;

      (d)   the Executive shall assume, obey, implement and execute such duties,
            directions, responsibilities, procedures, policies and lawful orders
            as may be determined or given from time to time by the Company; and

      (e)   the Executive shall report the results of her duties hereunder to
            the Company as it may request from time to time.

                                   ARTICLE 2
                                  COMPENSATION
2.1   Salary.

      (a)   For services rendered by the Executive during the Term, the
            Executive shall be paid throughout the Term a monthly salary,
            payable within 10 days after the end of each month (the "Salary").
<PAGE>

      (b)   During the first two months in which the Executive receives a
            Salary, the gross monthly Salary shall be US$ 6,000; during the
            third through fourth months in which the Executive receives a
            Salary, the gross monthly Salary shall be US$ 7,000; and thereafter
            the Executive's gross monthly Salary shall be US$ 7,700.

      (c)   The Salary shall be paid in NIS translated pursuant to the official
            representative rate of exchange of the US$ as published by the Bank
            of Israel on the payment date. Any deductions required to be made by
            the Company and submitted to relevant tax or other authorities will
            be deducted at source.

      (d)   The Executive's Assignment is included among the positions of
            management or those requiring a special degree of personal trust,
            and the Company is not able to supervise the number of working hours
            of the Executive; therefore the provisions of the Israel Hours of
            Work and Rest Law - 1951, will not apply to the Executive and she
            will not be entitled to any additional remuneration whatsoever for
            her work, with the exception of that specifically set out in this
            Agreement.

2.2   Options. The Executive shall be entitled to participate in the employee
      stock option plan to be adopted by the Parent Company (the "ESOP"), to an
      extent determined at the sole discretion of the Parent Company's Board of
      Directors, and only following and pending the adoption of the ESOP by the
      Parent Company.

2.3   Expenses. The Executive will be reimbursed by the Company for all
      reasonable business expenses incurred by the Executive in connection with
      her duties within previously approved budgets upon submission of a monthly
      statement of expenses. This includes, but not only, full use of cellular
      phone, use of one dedicated telephone/data line at home, daily newspaper,
      payments of expenses incurred when traveling abroad, per diem payments for
      travel abroad according to the rules set forth by the Israeli Tax
      Authorities and others. The Executive shall bear any tax payments
      resulting from the aforesaid, to the extant applicable.

2.4   Company Vehicle. The Executive shall be entitled to the use of a Licensing
      Class 4 vehicle, as shall be determined by the Company, for which the
      Company shall incur all reasonable expenses associated therewith, but
      excluding personal traffic fines and the like. The use of such car shall
      be subject to the Company's instructions, as may be amended from time to
      time. The Executive shall bear any tax payments resulting from the
      aforesaid, to the extent applicable.

2.5   Vacation; Recreation Pay. The Executive shall be entitled to cumulative
      paid vacations of 20 days per year. In addition, Executive shall be
      entitled to sick leave and Recreation Pay according to applicable law.
      Executive shall be entitled to cash redemption of vested vacation upon
      termination of this agreement, with or without cause, according to Israeli
      Labor Law and practice.

2.6   Deductions. The Executive acknowledges that all payments by the Company in
      respect of the services provided by the Executive shall be net of all
      amounts which the Company

<PAGE>

      as employer is required to deduct or withhold from Salary or other
      payments to an executive in accordance with statutory requirements
      (including, without limitation, income tax, employee contributions and
      unemployment insurance contributions).

                                   ARTICLE 3
                          SOCIAL INSURANCE AND BENEFITS

3.1   Managers Insurance. The Company shall insure Executive under an accepted
      "Manager's Insurance Scheme", which in each case shall provide insurance
      in the event of illness or disability (hereinafter referred to as the
      "Managers Insurance") as follows: (i) the Company shall pay an amount
      equal up to 7.5% of Executive's Salary towards the Managers Insurance for
      Executive's benefit and Disability Insurance and shall deduct 5% from
      Executive's Salary and pay such amount towards the Managers Insurance for
      Executive's benefit (the various components of the Managers Insurance
      shall be fixed at the discretion of Executive); and (ii) the Company shall
      pay an amount equal to 8 1/3% of Executive's Salary towards a fund for
      severance compensation which shall be payable to Executive upon severance,
      subject to provisions of Section 3.3 herein.

3.2   Keren Hishtalmut Fund. The Company and Executive shall open and maintain a
      Keren Hishtalmut Fund. The Company shall contribute to such Fund an amount
      equal to 7-1/2% of each monthly Salary payment, and Executive shall
      contribute to such Fund an amount of up to 2-1/2% of each monthly Salary
      payment. Executive hereby instructs the Company to transfer to such Fund
      the amount of Executive's and the Company's contribution from each monthly
      Salary payment. Notwithstanding the above, if the amounts to be
      contributed to the Keren Hishtalmut Fund will exceed the amount exempt
      from tax pursuant to the applicable tax regulations, any amount so
      exceeding shall not be transferred to such Fund but shall be added to the
      Salary.

3.3   Effect of Termination. Upon termination of this Agreement by either party,
      other than in circumstances constituting Cause (as defined below), the
      Company shall assign and transfer to the Executive, after Executive has
      met all of Executive's obligations hereunder in connection with such
      termination of employment, the ownership in the aforesaid Manager's
      Insurance and Keren Hishtalmut Fund. In the event that this Agreement is
      terminated in circumstances constituting Cause, the Company, in its
      absolute discretion, may retain its payments to such funds and release to
      the Executive only those sums contributed by Executive to such funds.

3.4   Liability Insurance Indemnification. Within a reasonable period of time
      following the signing of this agreement, the Company shall provide the
      Executive with coverage under a standard directors' and officers'
      liability insurance policy, at the Company's expense. In addition, the
      Executive shall be granted indemnification by the Parent Company in
      connection with her position therein.

<PAGE>

                                   ARTICLE 4
                                 CONFIDENTIALITY

4.1   Maintenance of Confidential Information. The Executive acknowledges that
      in the course of employment hereunder the Executive will, either directly
      or indirectly, have access to and be entrusted with information (whether
      oral, written or by inspection) relating to the Company or its Parent
      Company or their respective affiliates, associates or customers (the
      "Confidential Information"). For the purposes of this Agreement,
      "Confidential Information" includes, without limitation, any and all
      Developments (as defined herein), trade secrets, inventions, innovations,
      techniques, processes, formulas, drawings, designs, products, systems,
      creations, improvements, documentation, data, specifications, technical
      reports, customer lists, supplier lists, distributor lists, distribution
      channels and methods, retailer lists, reseller lists, employee
      information, financial information, sales or marketing plans, competitive
      analysis reports and any other thing or information whatsoever, whether
      copyrightable or uncopyrightable or patentable or unpatentable. The
      Executive acknowledges that the Confidential Information constitutes a
      proprietary right, which the Company is entitled to protect. Accordingly
      the Executive covenants and agrees that during the Term and thereafter
      until such time as all the Confidential Information becomes publicly known
      and made generally available through no action or inaction of the
      Executive, the Executive will keep in strict confidence the Confidential
      Information and shall not, without prior written consent of the Company,
      disclose, use or otherwise disseminate the Confidential Information,
      directly or indirectly, to any third party.

4.2   Exceptions. The general prohibition contained in Section 4.1 against the
      unauthorized disclosure, use or dissemination of the Confidential
      Information shall not apply in respect of any Confidential Information
      that:

      (a)   is available to the public generally in the form disclosed;

      (b)   becomes part of the public domain through no fault of the Executive;

      (c)   is already in the lawful possession of the Executive at the time of
            receipt of the Confidential Information; or

      (d)   is compelled by applicable law to be disclosed, provided that the
            Executive gives the Company prompt written notice of such
            requirement prior to such disclosure and provides assistance in
            obtaining an order protecting the Confidential Information from
            public disclosure.

4.3   Developments. Any information, technology, technical data or any other
      thing or documentation whatsoever which the Executive, either by himself
      or in conjunction with any third party, has conceived, made, developed,
      acquired or acquired knowledge of during the Executive's employment with
      the Company or which the Executive, either by himself or in conjunction
      with any third party, shall conceive, make, develop, acquire or acquire
      knowledge of (collectively the "Developments") during the Term or at any
      time thereafter during which the Executive is employed by the Company that
      is related to

<PAGE>

      conducting research and clinical study shall automatically form part of
      the Confidential Information and shall become and remain the sole and
      exclusive property of the Company. Accordingly, the Executive does hereby
      irrevocably, exclusively and absolutely assign, transfer and convey to the
      Company in perpetuity all worldwide right, title and interest in and to
      any and all Developments and other rights of whatsoever nature and kind in
      or arising from or pertaining to all such Developments created or produced
      by the Executive during the course of performing this Agreement,
      including, without limitation, the right to effect any registration in the
      world to protect the foregoing rights. The Company shall have the sole,
      absolute and unlimited right throughout the world, therefore, to protect
      the Developments by patent, copyright, industrial design, trademark or
      otherwise and to make, have made, use, reconstruct, repair, modify,
      reproduce, publish, distribute and sell the Developments, in whole or in
      part, or combine the Developments with any other matter, or not use the
      Developments at all, as the Company sees fit.

4.4   Protection of Developments. The Executive does hereby agree that, both
      before and after the termination of this Agreement, the Executive shall
      perform such further acts and execute and deliver such further
      instruments, writings, documents and assurances (including, without
      limitation, specific assignments and other documentation which may be
      required anywhere in the world to register evidence of ownership of the
      rights assigned pursuant hereto) as the Company shall reasonably require
      in order to give full effect to the true intent and purpose of the
      assignment made under Section 4.3 hereof. If the Company is for any reason
      unable, after reasonable effort, to secure execution by the Executive on
      documents needed to effect any registration or to apply for or prosecute
      any right or protection relating to the Developments, the Executive hereby
      designates and appoints the Company and its duly authorized officers and
      agents as the Executive's agent and attorney to act for and in the
      Executive's behalf and stead to execute and file any such document and do
      all other lawfully permitted acts necessary or advisable in the opinion of
      the Company to effect such registration or to apply for or prosecute such
      right or protection, with the same legal force and effect as if executed
      by the Executive.

4.5   Fiduciary Obligation. The Executive declares that the Executive's
      relationship to the Company is that of fiduciary, and the Executive agrees
      to act towards the Company and otherwise behave as a fiduciary of the
      Company.

4.6   Remedies. The parties to this Agreement recognize that any violation or
      threatened violation by the Executive of any of the provisions contained
      in this Article 4 will result in immediate and irreparable damage to the
      Company and that the Company could not adequately be compensated for such
      damage by monetary award alone. Accordingly, the Executive agrees that in
      the event of any such violation or threatened violation, the Company
      shall, in addition to any other remedies available to the Company at law
      or in equity, be entitled as a matter of right to apply to such relief by
      way of restraining order, temporary or permanent injunction and to such
      other relief as any court of competent jurisdiction may deem just and
      proper.

<PAGE>

4.7   Reasonable Restrictions. The Executive agrees that all restrictions in
      this Article 4 are reasonable and valid, and all defenses to the strict
      enforcement thereof by the Company are hereby waived by the Executive.

                                   ARTICLE 5
                                 NON-COMPETITION

5.1   Non Competition. Executive agrees and undertakes that she will not, so
      long as she is employed by the Company and for a period of 12 months
      following termination of her employment for whatever reason, directly or
      indirectly, as owner, partner, joint venture, stockholder, employee,
      broker, agent, principal, corporate officer, director, licensor or in any
      other capacity whatever engage in, become financially interested in, be
      employed by, or have any connection with any business or venture that
      competes with the Company's business, including any business which, when
      this Agreement terminates, the Company contemplates in good faith to be
      materially engaged in within 12 months thereafter, provided that the
      Company has taken demonstrable actions to promote such engagement or that
      the Company's Board of Directors has adopted a resolution authorizing such
      actions prior to the date of termination; provided, however, that
      Executive may own securities of any corporation which is engaged in such
      business and is publicly owned and traded but in an amount not to exceed
      at any one time one percent (1%) of any class of stock or securities of
      such company, so long as she has no active role in the publicly owned and
      traded company as director, employee, consultant or otherwise.

5.2   No Solicitation. Executive agrees and undertakes that during the period of
      her employment and for a period of 12 months following termination, she
      will not, directly or indirectly, including personally or in any business
      in which she is an officer, director or shareholder, for any purpose or in
      any place, employ any person (as an employee or consultant) employed by
      the Company at such time or during the preceding twelve months, unless
      such person has been terminated by the Company, provided however, that
      such person who is terminated by the Company may be employed by Executive
      as described above only after the expiration of twelve months after the
      effective date of such termination.

                                   ARTICLE 6
                                   TERMINATION

6.1   Termination For Cause or Disability. This Agreement may be terminated at
      any time by the Company without notice, for Cause or in the event of the
      Disability of Executive.

      For the purposes of this Agreement, "Cause" also means that the Executive
      shall have:

      (a)   committed an intentional act of fraud, embezzlement or theft in
            connection with the Executive's duties or in the course of the
            Executive's employment with the Company;

<PAGE>

      (b)   intentionally and wrongfully damaged property of the Company, or any
            of its respective affiliates, associates or customers;

      (c)   intentionally or wrongfully disclosed any of the Confidential
            Information;

      (d)   made material personal benefit at the expense of the Company without
            the prior written consent of the management of the Company;

      (e)   accepted shares or options or any other gifts or benefits from a
            vendor without the prior written consent of the management of the
            Company;

      (f)   fundamentally breached any of the Executive's material covenants
            contained in this Agreement; or (g) willfully and persistently,
            without reasonable justification, failed or refused to follow the
            lawful and proper directives of the Company specifying in reasonable
            detail the alleged failure or refusal and after a reasonable
            opportunity for the Executive to cure the alleged failure or
            refusal.

      For the purposes of this Agreement, an act or omission on the part of the
      Executive shall not be deemed "intentional," if it was due to an error in
      judgment or negligence, but shall be deemed "intentional" if done by the
      Executive not in good faith and without reasonable belief that the act or
      omission was in the best interests of the Company, or its respective
      affiliates, associates or customers.

      For the purposes of this Agreement, "Disability" shall mean any physical
      or mental illness or injury as a result of which Executive remains absent
      from work for a period of six (6) successive months, or an aggregate of
      six (6) months in any twelve (12) month period. Disability shall occur
      upon the end of such six-month period.

6.2   Severance for Termination With Cause. If the Company terminates the
      Executive's employment for Cause, then the Company will not be obligated
      to pay the Executive any severance payments or provide any notice
      whatsoever to the Executive.

      6.3 Termination Without Cause. Either the Executive or the Company may
      terminate the Executive's employment without Cause, for any reason
      whatsoever, with 30 days notice within the first year of the Executive's
      engagement and with 90 days prior written notice thereafter.

      6.4 The Notice Period.

      (a)   During the period following the notice of termination (the "Notice
            Period"), Executive shall cooperate with the Company and use her
            best efforts to assist the integration into the Company's
            organization of the person or persons who will assume Executive's
            responsibilities.

      (b)   This Agreement shall remain in full force and effect until the end
            of the Notice Period and there shall be no change in Executive's
            compensation terms or any of her obligations hereunder during such
            Notice period.

<PAGE>

      (c)   Notwithstanding sub-section (b) above, during the Notice Period the
            Company may, at its discretion, relieve Executive of her position,
            upon which Executive shall leave the Company. Such actions shall not
            derogate in any way or manner whatsoever from Executive's rights to
            receive the Salary until the end of the Notice period.

6.5   Limitation of Damages. It is agreed that in the event of termination of
      employment, neither the Company, nor the Executive shall be entitled to
      any notice, or payment in excess of that specified in this Article 6.

6.6   Return of Materials. Within three (3) days of any termination of
      employment hereunder, or upon any request by the Company at any time, the
      Executive will return or cause to be returned any and all Confidential
      Information and other assets of the Company (including all originals and
      copies thereof), which "assets" include, without limitation, hardware,
      software, keys, security cards and backup tapes that were provided to the
      Executive either for the purpose of performing the employment services
      hereunder or for any other reason. The Executive acknowledges that the
      Confidential Information and the assets are proprietary to the Company,
      and the Executive agrees to return them to the Company in the same
      condition as the Executive received such Confidential Information and
      assets.

6.7   Effect of Termination. Articles 3.3, 3.4, 4, 5 and 6.6 hereto shall remain
      in full force and effect after termination of this Agreement, for any
      reason whatsoever.

                                   ARTICLE 7
                             MUTUAL REPRESENTATIONS

7.1   Executive represents and warrants to the Company that the execution and
      delivery of this Agreement and the fulfillment of the terms hereof (i)
      will not constitute a default under or conflict with any agreement or
      other instrument to which she is a party or by which she is bound, and
      (ii) do not require the consent of any person or entity.

7.2   The Company represents and warrants to Executive that this Agreement has
      been duly authorized, executed and delivered by the Company and that the
      fulfillment of the terms hereof (i) will not constitute a default under or
      conflict with any agreement of other instrument to which it is a party or
      by which it is bound, and (ii) do not require the consent of any person of
      entity.

7.3   Each party hereto warrants and represents to the other that this Agreement
      constitutes the valid and binding obligation of such party enforceable
      against such party in accordance with its terms subject to applicable
      bankruptcy, insolvency, moratorium and similar laws affecting creditors'
      rights generally, and subject, as to enforceability, to general principles
      of equity (regardless if enforcement is sought in proceeding in equity or
      at law).

<PAGE>

                                   ARTICLE 8
                                    NOTICES

8.1   Notices. All notices required or allowed to be given under this Agreement
      shall be made either personally by delivery to or by facsimile
      transmission to the address as hereinafter set forth or to such other
      address as may be designated from time to time by such party in writing:

      (a)   in the case of the Company, to:

                  Oriens Life Sciences (Israel) Ltd.
                  23 Aminadav St., Tel Aviv
                  Attn: Dr. Shay Goldstein, CEO
                  Fax: 972-3-561-3465

            with a copy to

                  Ori Rosen, Adv.
                  Ori Rosen & Co. Law Offices, 1 Azrieli Center (Round Building)
                  Tel Aviv 67021, Israel
                  Fax: 972-3-607-4701
                  Email: ori@rosenlaw.co.il

      (b)   and in the case of the Executive, to the Executive's last residence
            address known to the Company.

8.2   Change of Address. Any party may, from time to time, change its address
      for service hereunder by written notice to the other party in the manner
      aforesaid.

                                   ARTICLE 9
                                    GENERAL

9.1   Entire Agreement. As of from the date hereof, any and all previous
      agreements, written or oral between the parties hereto or on their behalf
      relating to the employment of the Executive by the Company are null and
      void. The parties hereto agree that they have expressed herein their
      entire understanding and agreement concerning the subject matter of this
      Agreement and it is expressly agreed that no implied covenant, condition,
      term or reservation or prior representation or warranty shall be read into
      this Agreement relating to or concerning the subject matter hereof or any
      matter or operation provided for herein.

9.2   Personal Agreement. The provisions of this Agreement are in lieu of the
      provisions of any collective bargaining agreement, and therefore, no
      collective bargaining agreement shall apply with respect to the
      relationship between the parties hereto (subject to the applicable
      provisions of law).

<PAGE>

9.3   Further Assurances. Each party hereto will promptly and duly execute and
      deliver to the other party such further documents and assurances and take
      such further action as such other party may from time to time reasonably
      request in order to more effectively carry out the intent and purpose of
      this Agreement and to establish and protect the rights and remedies
      created or intended to be created hereby.

9.4   Waiver. No provision hereof shall be deemed waived and no breach excused,
      unless such waiver or consent excusing the breach is made in writing and
      signed by the party to be charged with such waiver or consent. A waiver by
      a party of any provision of this Agreement shall not be construed as a
      waiver of a further breach of the same provision.

9.5   Amendments in Writing. No amendment, modification or rescission of this
      Agreement shall be effective unless set forth in writing and signed by the
      parties hereto.

9.6   Assignment. Except as herein expressly provided, the respective rights and
      obligations of the Executive and the Company under this Agreement shall
      not be assignable by either party without the written consent of the other
      party and shall, subject to the foregoing, enure to the benefit of and be
      binding upon the Executive and the Company and their permitted successors
      or assigns. Nothing herein expressed or implied is intended to confer on
      any person other than the parties hereto any rights, remedies, obligations
      or liabilities under or by reason of this Agreement. 9.7 Severability. In
      the event that any provision contained in this Agreement shall be declared
      invalid, illegal or unenforceable by a court or other lawful authority of
      competent jurisdiction, such provision shall be deemed not to affect or
      impair the validity or enforceability of any other provision of this
      Agreement, which shall continue to have full force and effect.

9.8   Headings. The headings in this Agreement are inserted for convenience of
      reference only and shall not affect the construction or interpretation of
      this Agreement.

9.9   Number and Gender. Wherever the singular or masculine or neuter is used in
      this Agreement, the same shall be construed as meaning the plural or
      feminine or a body politic or corporate and vice versa where the context
      so requires.

9.10  Time. Time shall be of the essence of this Agreement.

9.11  Governing Law. This Agreement shall be construed and interpreted in
      accordance with the laws of the state of Israel applicable therein, and
      each of the parties hereto expressly attorns to the jurisdiction of the
      courts of the state of Israel. The sole and exclusive place of
      jurisdiction in any matter arising out of or in connection with this
      Agreement shall be the applicable Tel-Aviv court.

<PAGE>

9.12  Enurement. This Agreement is intended to bind and enure to the benefit of
      the Company, its successors and assigns, and the Executive and the
      personal legal representatives of the Executive.

                [Remainder of this page left intentionally blank]

<PAGE>

IN WITNESS WHEREOF the parties hereto have executed this Agreement effective as
of the date and year first above written.

ORIENS LIFE SCIENCES (ISRAEL) LTD.            EXECUTIVE

Sign:  /s/ Shay Goldstein                     /s/ Tamar Tzaban-Nahomov
       --------------------------             --------------------------
                                              Tamar Tzaban-Nahomov
Name:  Shay Goldstein
       --------------

Title: Chief Executive Officer
       -----------------------THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE AND HAVE BEEN ISSUED IN
RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933,
AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD
EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT
OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
APPLICABLE STATE SECURITIES LAWS.

               THESE WARRANTS WILL EXPIRE AND BECOME NULL AND VOID
                AT 4:30 P.M. (NEW YORK TIME) ON October 31, 2008

                             SHARE PURCHASE WARRANTS
                          TO PURCHASE COMMON SHARES OF
                          GAMMACAN INTERNATIONAL, INC.

                      incorporated in the State of Delaware

Warrant Certificate No.: _______

THIS IS TO CERTIFY THAT Bank Sal. Oppenheim jr. & Cie. (Switzerland) Ltd. (the
"Holder"), has the right to purchase, upon and subject to the terms and
conditions hereinafter referred to, up to 333,333 fully paid and non-assessable
common shares (the "Shares") in the capital of Gammacan International, Inc.
(hereinafter called the "Company") on or before 4:30 p.m. (New York time) on
October 31, 2008 (the "Expiry Date") at a price per Share (the "Exercise Price")
of US$1.00 on the terms and conditions attached hereto as Appendix "A" (the
"Terms and Conditions").

      1.    ONE (1) WARRANT AND THE EXERCISE PRICE ARE REQUIRED TO PURCHASE ONE
            SHARE. THIS CERTIFICATE REPRESENTS 333,333 WARRANTS.

      2.    These Warrants are issued subject to the Terms and Conditions, and
            the Warrant Holder may exercise the right to purchase Shares only in
            accordance with those Terms and Conditions.

      3.    Nothing contained herein or in the Terms and Conditions will confer
            any right upon the Holder hereof or any other person to subscribe
            for or purchase any Shares at any time subsequent to the Expiry
            Date, and from and after such time, this Warrant and all rights
            hereunder will be void and of no value.

IN WITNESS WHEREOF the Company has executed this Warrant Certificate this 31st
day of October, 2005.

GAMMACAN INTERNATIONAL, INC.

Per:     /s/ Vered Caplan
         --------------------------------------------
         Authorized Signatory

THESE SECURITIES WERE ISSUED IN AN OFFSHORETRANSACTION TO PERSONS WHO ARE NOT
U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE 1933 ACT) PURSUANT TO
REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE
"1933 ACT"). NONE OF THE SECURITIES TO WHICH THIS CERTIFICATE RELATES HAVE BEEN
REGISTERED UNDER THE 1933 ACT, OR ANY U.S. STATE SECURITIES LAWS, AND, UNLESS SO
REGISTERED, NONE MAY BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, IN THE UNITED
STATES OR TO U.S. PERSONS EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION
S UNDER THE 1933 ACT, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE
1933 ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT
SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE 1933 ACT AND IN EACH CASE ONLY
IN ACCORDANCE WITH ALL APPLICABLE SECURITIES LAWS. IN ADDITION, HEDGING
TRANSACTIONS INVOLVING THE SECURITIES MAYNOT BE CONDUCTED UNLESS IN ACCORDANCE
WITH THE 1933 ACT.

<PAGE>

                                  APPENDIX "A"

TERMS AND CONDITIONS dated October 31, 2005, attached to the Warrants issued by

Gammacan International, Inc.

1.    INTERPRETATION

1.1   Definitions

In these Terms and Conditions, unless there is something in the subject matter
or context inconsistent therewith:

      (a)   "Company" means Gammacan International, Inc. until a successor
            corporation will have become such as a result of consolidation,
            amalgamation or merger with or into any other corporation or
            corporations, or as a result of the conveyance or transfer of all or
            substantially all of the properties and estates of the Company as an
            entirety to any other corporation and thereafter "Company" will mean
            such successor corporation;

      (b)   "Company's Auditors" means an independent firm of accountants duly
            appointed as auditors of the Company;

      (c)   "Director" means a director of the Company for the time being, and
            reference, without more, to action by the directors means action by
            the directors of the Company as a Board, or whenever duly empowered,
            action by an executive committee of the Board;

      (d)   "herein", "hereby" and similar expressions refer to these Terms and
            Conditions as the same may be amended or modified from time to time;
            and the expression "Article" and "Section," followed by a number
            refer to the specified Article or Section of these Terms and
            Conditions;

      (e)   "person" means an individual, corporation, partnership, trustee or
            any unincorporated organization and words importing persons have a
            similar meaning;

      (f)   "shares" means the common shares in the capital of the Company as
            constituted at the date hereof and any shares resulting from any
            subdivision or consolidation of the shares;

      (g)   "Warrant Holders" or "Holders" means the holders of the Warrants;
            and

      (h)   "Warrants" means the warrants of the Company issued and presently
            authorized and for the time being outstanding.

1.2   Gender

Words importing the singular number include the plural and vice versa and words
importing the masculine gender include the feminine and neuter genders.

1.3   Interpretation not affected by Headings

The division of these Terms and Conditions into Articles and Sections, and the
insertion of headings are for convenience of reference only and will not affect
the construction or interpretation thereof.

1.4   Applicable Law

The Warrants will be construed in accordance with the laws of the state of
Delaware.

<PAGE>

2.    ISSUE OF WARRANTS

2.1   Additional Warrants

The Company may at any time and from time to time issue additional warrants or
grant options or similar rights to purchase shares of its capital stock.

2.2   Warrant to Rank Pari Passu

All Warrants and additional warrants, options or similar rights to purchase
shares from time to time issued or granted by the Company, will rank pari passu
whatever may be the actual dates of issue or grant thereof, or of the dates of
the certificates by which they are evidenced.

2.3   Issue in substitution for Lost Warrants

      (a)   In case a Warrant becomes mutilated, lost, destroyed or stolen, the
            Company, at its discretion, may issue and deliver a new Warrant of
            like date and tenor as the one mutilated, lost, destroyed or stolen,
            in exchange for and in place of and upon cancellation of such
            mutilated Warrant, or in lieu of, and in substitution for such lost,
            destroyed or stolen Warrant and the substituted Warrant will be
            entitled to the benefit hereof and rank equally in accordance with
            its terms with all other Warrants issued or to be issued by the
            Company.

      (b)   The applicant for the issue of a new Warrant pursuant hereto will
            bear the cost of the issue thereof and in case of loss, destruction
            or theft furnish to the Company such evidence of ownership and of
            loss, destruction, or theft of the Warrant so lost, destroyed or
            stolen as will be satisfactory to the Company in its discretion and
            such applicant may also be required to furnish indemnity in amount
            and form satisfactory to the Company in its discretion, and will pay
            the reasonable charges of the Company in connection therewith.

2.4   Warrant Holder Not a Shareholder

The holding of a Warrant will not constitute the Holder thereof a shareholder of
the Company, nor entitle him to any right or interest in respect thereof except
as in the Warrant expressly provided.

3.    NOTICE

3.1   Notice to Warrant Holders

Any notice required or permitted to be given to the Holders will be in writing
and may be given by prepaid registered post, electronic facsimile transmission
or other means of electronic communication capable of producing a printed copy
to the address of the Holder appearing on the Holder's Warrant or to such other
address as any Holder may specify by notice in writing to the Company, and any
such notice will be deemed to have been given and received by the Holder to whom
it was addressed if mailed, on the third day following the mailing thereof, if
by facsimile or other electronic communication, on successful transmission, or,
if delivered, on delivery; but if at the time or mailing or between the time of
mailing and the third business day thereafter there is a strike, lockout, or
other labour disturbance affecting postal service, then the notice will not be
effectively given until actually delivered.

3.2   Notice to the Company

Any notice required or permitted to be given to the Company will be in writing
and may be given by prepaid registered post, electronic facsimile transmission
or other means of electronic communication capable of producing a printed copy
to the address of the Company set forth below or such other address as the
Company may specify by notice in writing to the Holder, and any such notice will
be deemed to have been given and received by the Company to whom it was
addressed if mailed, on the third day following the mailing thereof, if by
facsimile or other electronic communication, on successful transmission, or, if
delivered, on delivery; but if at the time or mailing or between the time of
mailing and the third business day thereafter there is a strike, lockout, or
other labour disturbance affecting postal service, then the notice will not be
effectively given until actually delivered:

<PAGE>

                  Gammacan International, Inc.
                  11 Ben Gurion Street
                  54100 Givat Shmuel, Israel

                  Attention:  Vered Caplan

                  Fax No. 972 3 5324038

                  with a copy to:

                  Sichenzia Ross Friedman Ference LLP
                  1065 Avenue of the Americas
                  New York, New York 10018

                  Attention: Thomas A. Rose, Esq.

                  Fax: 212.930.9725

4.    EXERCISE OF WARRANTS

4.1   Method of Exercise of Warrants

      (a)   The right to purchase shares conferred by the Warrants may be
            exercised by the Holder surrendering the Warrant Certificate
            representing same, with a duly completed and executed subscription
            in the form attached hereto and a bank draft or certified check
            payable to or to the order Company, for the purchase price
            applicable at the time of surrender in respect of the shares
            subscribed for in lawful money of the United States of America, to
            the Company at the address set forth in, or from time to time
            specified by the Company pursuant to, Section 3.2.

      (b)   If at any time after one year from the date of issuance of this
            Warrant there is no effective Registration Statement registering the
            resale of the shares underlying this Warrant by the Holder at such
            time, this Warrant may also be exercised at such time by means of a
            "cashless exercise" in which the Holder shall be entitled to receive
            a certificate for the number of shares equal to the quotient
            obtained by dividing [(A-B) (X)] by (A), where:

            (A)   = the closing bid price of the Common Stock on the trading day
                  immediately preceding the date of such election;

            (B)   = the Exercise Price of this Warrant, as adjusted; and

            (X)   = the number of shares issuable upon exercise of this Warrant
                  in accordance with the terms of this Warrant by means of a
                  cash exercise rather than a cashless exercise.

4.2   Effect of Exercise of Warrants

      (a)   Upon surrender and payment as aforesaid the shares so subscribed for
            will be deemed to have been issued and such person or persons will
            be deemed to have become the Holder or Holders of record of such
            shares on the date of such surrender and payment, and such shares
            will be issued at the subscription price in effect on the date of
            such surrender and payment.

<PAGE>

      (b)   Within five business days after surrender and payment as aforesaid,
            the Company will forthwith cause to be delivered to the person or
            persons in whose name or names the shares so subscribed for are to
            be issued as specified in such subscription or mailed to him or them
            at his or their respective addresses specified in such subscription,
            a certificate or certificates for the appropriate number of shares
            not exceeding those which the Warrant Holder is entitled to purchase
            pursuant to the Warrant surrendered.

      (c)   If the Company fails to deliver to the Holder a certificate or
            certificates representing the shares within five trading days from
            the delivery of an exercise notice, then the Holder will have the
            right to rescind such exercise.

4.3   Subscription for Less Than Entitlement

The Holder of any Warrant may subscribe for and purchase a number of shares less
than the number which he is entitled to purchase pursuant to the surrendered
Warrant. In the event of any purchase of a number of shares less than the number
which can be purchased pursuant to a Warrant, the Holder thereof upon exercise
thereof will in addition be entitled to receive a new Warrant in respect of the
balance of the shares which he was entitled to purchase pursuant to the
surrendered Warrant and which were not then purchased.

4.4   Warrants for Fractions of Shares

To the extent that the Holder of any Warrant is entitled to receive on the
exercise or partial exercise thereof a fraction of a share, such right may be
exercised in respect of such fraction only in combination with another Warrant
or other Warrants which in the aggregate entitle the Holder to receive a whole
number of such shares.

4.5   Expiration of Warrants

After the expiration of the period within which a Warrant is exercisable, all
rights thereunder will wholly cease and terminate and such Warrant will be void
and of no effect.

4.6   Time of Essence

Time will be of the essence hereof.

4.7   Subscription Price

Each Warrant is exercisable at a price per share (the "Exercise Price") of
US$1.00. One (1) Warrant and the Exercise Price are required to subscribe for
each share during the term of the Warrants.

4.8   Adjustment of Exercise Price

      (a)   The Exercise Price and the number of shares deliverable upon the
            exercise of the Warrants will be subject to adjustment in the event
            and in the manner following:

            (i)   If and whenever the Company issues or sells any shares of the
                  Company for an effective consideration per share of less than
                  the then Exercise Price or for no consideration (such lower
                  price, the "Base Share Price"), then, the Exercise Price shall
                  be reduced to equal the Base Share Price. Such adjustment
                  shall be made whenever shares of the Company are issued.

            (ii)  If and whenever the shares at any time outstanding are
                  subdivided into a greater or consolidated into a lesser number
                  of shares the Exercise Price will be decreased or increased
                  proportionately as the case may be; upon any such subdivision
                  or consolidation the number of shares deliverable upon the
                  exercise of the Warrants will be increased or decreased
                  proportionately as the case may be.

<PAGE>

            (iii) In case of any capital reorganization or of any
                  reclassification of the capital of the Company or in the case
                  of the consolidation, merger or amalgamation of the Company
                  with or into any other Company (hereinafter collectively
                  referred to as a "Reorganization"), each Warrant will after
                  such Reorganization confer the right to purchase the number of
                  shares or other securities of the Company (or of the Company's
                  resulting from such Reorganization) which the Warrant Holder
                  would have been entitled to upon Reorganization if the Warrant
                  Holder had been a shareholder at the time of such
                  Reorganization.

                  In any such case, if necessary, appropriate adjustments will
                  be made in the application of the provisions of this Article
                  Four relating to the rights and interest thereafter of the
                  Holders of the Warrants so that the provisions of this Article
                  Four will be made applicable as nearly as reasonably possible
                  to any shares or other securities deliverable after the
                  Reorganization on the exercise of the Warrants.

                  The subdivision or consolidation of shares at any time
                  outstanding into a greater or lesser number of shares (whether
                  with or without par value) will not be deemed to be a
                  Reorganization for the purposes of this clause 4.8(a)(ii).

      (b)   The adjustments provided for in this Section 4.8 are cumulative and
            will become effective immediately after the record date or, if no
            record date is fixed, the effective date of the event which results
            in such adjustments.

4.9   Determination of Adjustments

If any questions will at any time arise with respect to the Exercise Price or
any adjustment provided for in Section 4.8, such questions will be conclusively
determined by the Company's Auditors, or, if they decline to so act any other
firm of certified public accountants in the United States of America that the
Company may designate and who will have access to all appropriate records and
such determination will be binding upon the Company and the Holders of the
Warrants.

5.    COVENANTS BY THE COMPANY

5.1   Reservation of Shares

The Company will reserve and there will remain unissued out of its authorized
capital a sufficient number of shares to satisfy the rights of purchase provided
for herein and in the Warrants should the Holders of all the Warrants from time
to time outstanding determine to exercise such rights in respect of all shares
which they are or may be entitled to purchase pursuant thereto and hereto.

6.    WAIVER OF CERTAIN RIGHTS

6.1   Immunity of Shareholders, etc.

The Warrant Holder, as part of the consideration for the issue of the Warrants,
waives and will not have any right, cause of action or remedy now or hereafter
existing in any jurisdiction against any past, present or future incorporator,
shareholder, Director or Officer (as such) of the Company for the issue of
shares pursuant to any Warrant or on any covenant, agreement, representation or
warranty by the Company herein contained or in the Warrant.

<PAGE>

7.    MODIFICATION OF TERMS, MERGER, SUCCESSORS

7.1   Modification of Terms and Conditions for Certain Purposes

From time to time the Company may, subject to the provisions of these presents,
modify the Terms and Conditions hereof, for the purpose of correction or
rectification of any ambiguities, defective provisions, errors or omissions
herein.

7.2   Warrants Not Transferable

The Warrant and all rights attached to it are not transferable.

<PAGE>

                              FORM OF SUBSCRIPTION

TO:      Gammacan International, Inc.
         11 Ben Gurion Street
         54100 Givat Shmuel, Israel

The undersigned Holder of the within Warrants hereby subscribes for
___________________ common shares (the "Shares") of Gammacan International, Inc.
(the "Company) pursuant to the within Warrants at US$1.00 per Share on the terms
specified in the said Warrants. This subscription is accompanied by a certified
cheque or bank draft payable to or to the order of the Company for the whole
amount of the purchase price of the Shares.

The undersigned hereby directs that the Shares be registered as follows:

NAME(S) IN FULL                   ADDRESS(ES)               NUMBER OF SHARES
---------------                   -----------               ----------------

-----------------------  ------------------------------  -----------------------

-----------------------  ------------------------------  -----------------------

-----------------------  ------------------------------  -----------------------

                           TOTAL:
                                                         -----------------------

(Please print full name in which share certificates are to be issued, stating
whether Mr., Mrs. or Miss is applicable).

DATED this _____ day of ______________________, 200___.

In the presence of:

------------------------------------------    ----------------------------------
Signature of Witness                          Signature of Warrant Holder

Please print below your name and address in full.

Name (Mr./Mrs./Miss)
                     -----------------------------------------------------------

Address
                     -----------------------------------------------------------

                     -----------------------------------------------------------

                          INSTRUCTIONS FOR SUBSCRIPTION

The signature to the subscription must correspond in every particular with the
name written upon the face of the Warrant without alteration or enlargement or
any change whatever. If there is more than one subscriber, all must sign.

In the case of persons signing by agent or attorney or by personal
representative(s), the authority of such agent, attorney or representative(s) to
sign must be proven to the satisfaction of the Company.

If the Warrant certificate and the form of subscription are being forwarded by
mail, registered mail must be employed.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}]]